Up next

How Will the Pharma Industry Perform in 2024 & the Near Term?

With 2024 well underway, the crucial question for both bio/pharma companies and their suppliers is: how will the industry perform in 2024 and the near term? Get the answer to that all-important question at the Pharma Industry Outlook education program at DCAT Week.

With 2024 well underway, the crucial question for both bio/pharma companies and their suppliers is: how will the industry perform in 2024 and the near term? Get the answer to that all-important question at the Pharma Industry Outlook education program at DCAT Week.

Getting the latest market analysis and data

Graham Lewis 
Vice President, Global Pharma Strategy 
IQVIA

What are the key growth indicators for the global bio/pharmaceutical market in 2024 and over the next several years, and how will the industry perform over this time?  That is the trillion-dollar question for the bio/pharma industry.

DCAT Week’s flagship program, Pharma Industry Outlook, will answer that question by providing valuable market intelligence on the current and projected performance of the bio/pharma industry. Graham Lewis, Vice President of Global Pharma Strategy, IQVIA, a business intelligence firm regarded as the gold standard for bio/pharma market analysis, will provide the latest market data and trends.

COVID-19 vaccines and therapeutics had been a boon for the industry, but with lower growth for these products, how will the industry perform relative to pre-pandemic growth trends? Is the industry’s performance trending upward or not? The program will examine the growth prospects and factors influencing performance for: innovator and generic drugs; leading therapeutic sectors, both pipelines and commercial products; and developed and emerging markets.

Daniel Cohen 
Managing Director & Global Head of Pharma Outsourcing Investment Banking
Morgan Stanley

A CMDO/CMO financial outlook
The performance of the industry as a whole is a factor in determining the health of the market for pharmaceutical outsourcing, which is further influenced by other factors. The program will also feature a Wall Street view of the CDMO/CMO sector, with Daniel Cohen, Managing Director & Global Head of Pharma Outsourcing Investment Banking, Morgan Stanley, providing a financial overview of the CDMO/CMO sector: performance & investor valuations. He will provide an analysis of key mergers & acquisitions and other trends impacting sector performance.

Pharma Industry Outlook will be held at the InterContinental Barclay Hotel, Grand Ballroom on Monday, March 18, 2023: 2:30 – 4:30 PM; Doors open at 2:00 PM for pre-program networking. Plus, Post-Program Attendee Networking Reception: 4:30 to 6:00 PM. 

Information on the program, including how to register, may be found here.

Recent Feature Articles

A New Round in US Pharma Tariffs: What’s at Play?

By
President Trump announced this week a phased plan to impose tariffs on imported generic drugs into the US as a means to encourage US-based production of generics, and a previously announced executive action for tariffs on patented drugs is coming due. 

In Vivo Cell Therapies: Solving Mfg Obstacles?

By
Several bio/pharma majors are making a play in in vivo cell therapies with recent $1-billion-plus acquisitions with an aim for both clinical and manufacturing benefits. Are in vivo cell therapies the up-and-coming segment in advanced therapies?

J&J Aims To Be $100-Bn Company; Begins Supply-Chain Restructuring

By
Johnson & Johnson is aiming to cross the $100-billion revenue mark in 2026 and is beginning a multi-year supply-chain restructuring program in its Innovative Medicine segment.

Solid Dosage Drugs: Keeping Pace in New Drug Approvals

By
Solid dosage drugs are a steady segment in the global bio/pharma industry, but how do they measure in new drug approvals? A look at the dosage forms of new drug approvals thus far in 2026 and the market potential of some key solid dosage drugs.